Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway (2019)

Peer-Reviewed Study · Jiang L; Wang P; Sun YJ; Wu YJ · June 2019

Jiang L et al., 2019-06: Study in vincristine- and adriamycin-resistant colorectal, breast and CML lines plus two mouse models reporting that low-dose ivermectin re-sensitises resistant tumours to chemotherapy by downregulating P-glycoprotein through EGFR inhibition rather than by blocking P-gp directly.

Mechanistically, ivermectin reversed the resistance mainly by reducing the expression of P-glycoprotein (P-gp) via inhibiting the epidermal growth factor receptor (EGFR), not by directly inhibiting P-gp activity.

n/a (HTML full text)

Jiang L et al., 2019-06: Study in vincristine- and adriamycin-resistant colorectal, breast and CML lines plus two mouse models reporting that low-dose ivermectin re-sensitises resistant tumours to chemotherapy by downregulating P-glycoprotein through EGFR inhibition rather than by blocking P-gp directly. Study type: resistant cell lines (HCT-8, MCF-7, K562) + nude mouse HCT-8 xenograft + NOD/SCID K562 model. N: 6 mice per group. Country: China (Institute of Zoology, Chinese Academy of Sciences). Dose: ivermectin 2 mg/kg/day intraperitoneal for 27 days, with vincristine 0.2 mg/kg/day; comparator: vehicle, vincristine alone, ivermectin alone. Funder: National Natural Science Foundation of China 31672366. Declared COI: 'The authors declare that they have no competing interests.' PARTLY SUPPORTS because the paper explicitly says the mechanism is NOT direct P-gp inhibition but P-gp downregulation via EGFR – the prompt's 'P-glycoprotein inhibition' framing is therefore imprecise for this paper. Study type: animal.